AbbVie Inc.ABBVNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +3.83% | +5.60% | +8.39% | +6.65% | +9.10% |
| Gross Profit Growth | +37.70% | +24.53% | +13.69% | +26.90% | +20.86% |
| EBITDA Growth | +2.95% | -86.11% | -1.98% | -13.17% | -29.47% |
| Operating Income Growth | +67.95% | -146.64% | +33.42% | +46.62% | +27.67% |
| Net Income Growth | -12.20% | -102.68% | -6.06% | -31.09% | -88.08% |
| EPS Growth | -12.00% | -103.93% | -6.49% | -31.17% | -88.64% |
| EPS Diluted Growth | -12.00% | -103.93% | -6.49% | -31.17% | -88.64% |
| Weighted Average Shares Growth | +0.11% | +0.17% | -0.06% | +0.17% | +0.17% |
| Weighted Average Shares Diluted Growth | +0.06% | +0.06% | -0.06% | +0.06% | +0.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -28.08% | +48.29% | -59.53% | +126.90% | +28.95% |
| Free Cash Flow Growth | -29.33% | +48.57% | -63.61% | +140.59% | +44.82% |
| Receivables Growth | +0.53% | -2.12% | +4.42% | +7.79% | +11.31% |
| Inventory Growth | +11.78% | +2.00% | +6.62% | +17.59% | +10.97% |
| Asset Growth | +5.29% | +0.33% | -8.54% | -3.35% | -6.64% |
| Book Value per Share Growth | -50.18% | -67.96% | -82.26% | +0.00% | +0.00% |
| Debt Growth | +17.01% | +12.84% | -5.56% | -0.22% | -3.29% |
| R&D Expense Growth | +23.62% | +206.65% | +6.60% | +7.80% | +5.35% |
| SG&A Expenses Growth | +24.70% | -9.83% | -0.66% | -4.71% | -19.62% |